1. Home
  2. BFS vs IRWD Comparison

BFS vs IRWD Comparison

Compare BFS & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BFS

Saul Centers Inc.

HOLD

Current Price

$34.26

Market Cap

809.1M

Sector

Real Estate

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$4.35

Market Cap

663.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFS
IRWD
Founded
1993
1998
Country
United States
United States
Employees
98
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
809.1M
663.6M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
BFS
IRWD
Price
$34.26
$4.35
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$44.00
$7.67
AVG Volume (30 Days)
43.8K
1.6M
Earning Date
05-11-2026
05-11-2026
Dividend Yield
6.92%
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.15
Revenue
N/A
$298,276,000.00
Revenue This Year
$0.30
$57.95
Revenue Next Year
$5.67
$4.39
P/E Ratio
$30.48
$27.77
Revenue Growth
N/A
8.88
52 Week Low
$29.16
$0.55
52 Week High
$35.45
$5.78

Technical Indicators

Market Signals
Indicator
BFS
IRWD
Relative Strength Index (RSI) 54.84 60.37
Support Level $32.42 $3.80
Resistance Level $34.94 $4.50
Average True Range (ATR) 0.63 0.26
MACD 0.03 0.02
Stochastic Oscillator 68.56 82.69

Price Performance

Historical Comparison
BFS
IRWD

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: